Amgen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

19.03.17	Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients (PR Newswire)
19.03.17	Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In Study (RTTNews)
18.03.17	Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study (PR Newswire)
17.03.17	MÄRKTE USA/Nach ziellosem Auf und Ab ein kleines Minus (Dow Jones)
17.03.17	Amgen cholesterol drug cuts heart attack, stroke risk but shares fall (Reuters)
17.03.17	Amgen Says Repatha Reduces Risk Of Hard Major Adverse Cardiovascular Events (RTTNews)
17.03.17	Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues (PR Newswire)
16.03.17	Amgen To Present At The Oppenheimer Global Health Care Conference (PR Newswire)
16.03.17	The Most Promising Biotech Innovation of 2017 (PR Newswire)
14.03.17	Repatha® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology' (PR Newswire)
14.03.17	Amgen To Webcast Investor Meeting At Upcoming American College Of Cardiology Scientific Sessions (PR Newswire)
13.03.17	Amgen Reports Positive Top-line Results From Repatha Phase 3 Study - Quick Facts (RTTNews)
13.03.17	Repatha® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study (PR Newswire)
07.03.17	Amgen Announces 2017 Second Quarter Dividend (PR Newswire)
07.03.17	NICE Recommends Amgen's Vectibix® (panitumumab) for Metastatic Colorectal Cancer for Previously Untreated Patients (PR Newswire)
06.03.17	Amgen Highlights Landmark Repatha® (Evolocumab) Cardiovascular Outcomes Study Amongst Data To Be Presented At ACC.17 (PR Newswire)
03.03.17	Amgen Presents Overall Survival Data From KYPROLIS® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop (PR Newswire)
02.03.17	Amgen To Present At The Cowen And Company 37th Annual Health Care Conference (PR Newswire)
01.03.17	BLINCYTO® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy (PR Newswire)
01.03.17	Amgen To Present New KYPROLIS® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop (PR Newswire)
28.02.17	Amgen: Phase 3 Trial Results Confirm Superiority Of KYPROLIS Over Velcade (RTTNews)
28.02.17	Phase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients (PR Newswire)
27.02.17	Biotech Stocks Facing FDA Decision In March (RTTNews)
21.02.17	Repatha® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option (PR Newswire)
21.02.17	Immunotherapy Companies Leading the Charge for Treating Cancer (PR Newswire)
14.02.17	Amgen Submits SBLA For Blincyto - Quick Facts (RTTNews)
14.02.17	Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (PR Newswire)
09.02.17	Sanofi Says Appeals Court Grants Stay Of Permanent Injunction For Praluent (RTTNews)
08.02.17	FLXN Gets FDA Date, KTOV In Crosshairs, It's A Thumbs Up For AMGN (RTTNews)
08.02.17	FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis (PR Newswire)
07.02.17	Amgen - Angriff auf das Allzeithoch (finanzen.ch)
06.02.17	Technical Reports on Biotech Stocks -- Amgen, Array BioPharma, Merrimack Pharma, and Alexion Pharma (PR Newswire)
06.02.17	ESPR, MDCO Riding High, New Uses For MRK's Old Drug, DBVT In Full Smile(e) (RTTNews)
03.02.17	MÄRKTE USA/Payrolls und Deregulierung treiben Börsen an (Dow Jones)
03.02.17	BetterInvesting Magazine Releases April Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use (PR Newswire)
03.02.17	Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors (PR Newswire)
03.02.17	MÄRKTE USA/US-Arbeitsmarktbericht treibt Wall Street an (Dow Jones)
03.02.17	MÄRKTE USA: US-Arbeitsmarktbericht dürfte Wall Street antreiben (Dow Jones)
03.02.17	Amgen erfreut mit starken Zahlen und positiver Medikamentenstudie (AWP)
02.02.17	Amgen: FOURIER Trial On Repatha Meets Its Primary Composite Endpoints (RTTNews)
02.02.17	Amgen Issues FY17 Guidance - Quick Facts (RTTNews)
02.02.17	Amgen Inc. Q4 Earnings Rise 9% (RTTNews)
02.02.17	Amgen Reports Fourth Quarter And Full Year 2016 Financial Results (PR Newswire)
02.02.17	Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study (PR Newswire)
01.02.17	Experten: Pharmakonzerne kommen bei Treffen mit Trump glimpflich davon (AWP)
30.01.17	Amgen Announces Webcast of 2016 Fourth Quarter and Full Year Financial Results (PR Newswire)
30.01.17	RGLS Disappointed, NOVN Loses Face Over Acne Trial Data, AMGN Abuzz (RTTNews)
27.01.17	Amgen Gets Positive CHMP Opinion For ABP 501 To Treat Inflammatory Diseases (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

15:58		Verluste in Frankfurt: TecDAX präsentiert sich leichter
15:58		SDAX aktuell: SDAX am Nachmittag in Rot
15:58		Dienstagshandel in Europa: Anleger lassen Euro STOXX 50 nachmittags steigen
15:12		TELL me! - der Schweizer Trading Podcast: Ausblick 2025: stabil bis positiv - Dividenden Titel: Coca-Cola, Sanofi und Evonik
13:08		JP Morgan Chase & Co. gibt Bayer-Aktie Neutral
12:26		Schwacher Handel in Frankfurt: So entwickelt sich der SDAX am Mittag
12:26		Schwacher Wochentag in Frankfurt: TecDAX zeigt sich mittags leichter
10:02		EURO STOXX 50-Wert Sanofi-Aktie: So viel Gewinn hätte ein Investment in Sanofi von vor 10 Jahren eingefahren

15:58

Verluste in Frankfurt: TecDAX präsentiert sich leichter

15:58

SDAX aktuell: SDAX am Nachmittag in Rot

15:58

Dienstagshandel in Europa: Anleger lassen Euro STOXX 50 nachmittags steigen

15:12

TELL me! - der Schweizer Trading Podcast: Ausblick 2025: stabil bis positiv - Dividenden Titel: Coca-Cola, Sanofi und Evonik

13:08

JP Morgan Chase & Co. gibt Bayer-Aktie Neutral

12:26

Schwacher Handel in Frankfurt: So entwickelt sich der SDAX am Mittag

12:26

Schwacher Wochentag in Frankfurt: TecDAX zeigt sich mittags leichter

10:02

EURO STOXX 50-Wert Sanofi-Aktie: So viel Gewinn hätte ein Investment in Sanofi von vor 10 Jahren eingefahren

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Geberit	542.60	1.61 %	K V
CieFinRichemont	127.65	1.43 %	K V
Sika	235.00	1.16 %	K V
Part Grp Hldg	1’295.00	0.97 %	K V
UBS Group	28.79	0.81 %	K V
Logitech Intl	71.78	-1.07 %	K V
Lonza Grp	521.80	-1.32 %	K V
Alcon	76.96	-1.41 %	K V
Sonova Hldg	295.40	-1.80 %	K V
Swiss Life Hldg	693.20	-4.31 %	K V

Nachrichten zu Amgen Inc.

Aktien Top/Flop

Amgen Peer Group Nachrichten

Meistgelesene Nachrichten